ArticleScientific reports2026
Morin improves postoperative cognitive dysfunction by mediating the miR-138-5p/SIRT1 axis to regulate ferroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis: an emerging key mechanism linking aging, surgical and anesthetic exposure to postoperative cognitive dysfunction.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to explore whether Morin could improve postoperative cognitive dysfunction (POCD) by inhibiting hippocampal ferroptosis through miR-138-5p/SIRT1. Morin improves the cognitive function of POCD mice by inhibiting the expression of miR-138-5p and promoting the expression of SIRT1 protein. When detecting ferroptosis-related indicators (such as GSH, MDA, and iron ion levels), it was found that miR-138-5p agomir blocked the regulatory effect of Morin on these indicators. Protein detection showed that Morin regulated the ferroptosis process by controlling the miR-138-5p/SIRT1 axis to affect the expression of p53, SLC7A11, and GPX4. In vitro cell experiments showed that after Erastin induction, the GSH level in HT22 cells decreased, the MDA and Fe2+ contents increased, and the ROS fluorescence intensity increased; after Morin treatment, these oxidative stress indicators were significantly improved, the expression of SIRT1, SLC7A11 and GPX4 increased, and the expression of p53 decreased. The miR-138-5p mimic aggravated the upregulation of oxidative stress and the regulation of ferroptosis-related genes, while the miR-138-5p inhibitor had the opposite effect. Morin improved cognitive function and neuronal morphology in POCD mice by inhibiting miR-138-5p and upregulating SIRT1. It also inhibited ferroptosis through the miR-138-5p/SIRT1 pathway, further confirming its protective role in POCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.